Breaking News Instant updates and real-time market news.

SAGE

Sage Therapeutics

$91.90

2.11 (2.35%)

10:18
12/07/17
12/07
10:18
12/07/17
10:18

Canaccord ups Sage target to $191 on 'unequivocally positive' data

Canaccord Genuity analyst John Newman raised his price target for Sage Therapeutics to $191 from $140 after the company reported Phase II trial results for SAGE-217 in major depressive disorder. The stock in early trading is up 66%, or $60.86, to $152.76. The data are "unequivocally positive" with a statistically significant effect versus placebo after the first dose, Newman tells investors in a research note. By comparison, currently marketed selective serotonin reuptake inhibitor depression drugs often take months to show an effect, the analyst points out. Further, he views SAGE-217's safety as "clean" and "highly encouraging." While admitting some investors may want to take profits on today's profits, Newman thinks Sage's long-range prospects are positive and he maintains a Buy rating on the shares.

  • 07

    Dec

SAGE Sage Therapeutics
$91.90

2.11 (2.35%)

11/27/17
RBCM
11/27/17
NO CHANGE
Target $137
RBCM
Outperform
Sage Therapeutics price target lowered to $137 from $145 at RBC Capital
RBC Capital analyst Brian Abrahams lowered his price target on Sage Therapeutics to $137 from $145, modelling a 40% probability of success and the possibility of more non-responders in the Phase 2B SAGE-217 for major depressive disorder - MDD - treatment. Abrahams keeps Outperform rating, saying the risk-reward profile is still attractive given the likelihood of "many additional shots on goal even if MDD fails", as negative outcome would not necessarily impact the overall prospects of the oral program in post-partum depression.
12/07/17
LEER
12/07/17
NO CHANGE
LEER
Outperform
Sage Therapeutics '217 MDD data looks like best case scenario, says Leerink
Leerink analyst Paul Matteis notes that Sage Therapeutics announced positive data for SAGE-217 in its phase 2 randomized, placebo-controlled study in major depressive disorder, or MDD. The analyst believes the data looks like best case scenario and expects the stock to trade up significantly today. He reiterates an Outperform rating on the shares.
12/07/17
JPMS
12/07/17
NO CHANGE
JPMS
Sage Therapeutics data 'best-case scenario,' says JPMorgan
JPMorgan analyst Cory Kasimov views this morning's Phase 2 trial data of SAGE-217 in major depressive disorder as a "best-case scenario." The analyst expects the stock to be up "sharply" today given the strength of the data. He has an Overweight rating on Sage shares.
12/07/17
ADAM
12/07/17
NO CHANGE
Target $191
ADAM
Buy
Sage Therapeutics price target raised to $191 from $140 at Canaccord

TODAY'S FREE FLY STORIES

AAPL

Apple

$186.81

-5.42 (-2.82%)

20:46
11/14/18
11/14
20:46
11/14/18
20:46
Hot Stocks
Apple supplier AMS AG discontinues FY18 targets »

Ams updates its fourth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

WEI

Weidai

$0.00

(0.00%)

20:33
11/14/18
11/14
20:33
11/14/18
20:33
Syndicate
Weidai 4.5M share IPO priced at $10.00 »

The deal was priced at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

CPB

Campbell Soup

$39.16

-0.1 (-0.25%)

20:31
11/14/18
11/14
20:31
11/14/18
20:31
Hot Stocks
Campbell Soup responds to ISS regarding board elections »

Campbell Soup issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

CRM

Salesforce

$129.25

-2.93 (-2.22%)

20:25
11/14/18
11/14
20:25
11/14/18
20:25
Periodicals
Breaking Periodicals news story on Salesforce »

Salesforce to accommodate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 27

    Nov

  • 27

    Nov

  • 28

    Nov

  • 29

    Nov

  • 06

    Dec

  • 11

    Dec

  • 03

    Mar

WMT

Walmart

$101.58

-1.37 (-1.33%)

, JCP

J.C. Penney

$1.23

-0.05 (-3.91%)

20:25
11/14/18
11/14
20:25
11/14/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

WMT

Walmart

$101.58

-1.37 (-1.33%)

JCP

J.C. Penney

$1.23

-0.05 (-3.91%)

BERY

Berry Global

$45.91

-0.49 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

BHVN

Biohaven Pharmaceutical

$33.70

-3.18 (-8.62%)

19:53
11/14/18
11/14
19:53
11/14/18
19:53
Recommendations
Biohaven Pharmaceutical analyst commentary  »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 27

    Nov

LOXO

Loxo Oncology

$143.69

-15.62 (-9.80%)

19:51
11/14/18
11/14
19:51
11/14/18
19:51
Initiation
Loxo Oncology initiated  »

Loxo Oncology initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 15

    Nov

  • 26

    Nov

  • 27

    Nov

OCUL

Ocular Therapeutix

$5.06

-0.25 (-4.71%)

19:50
11/14/18
11/14
19:50
11/14/18
19:50
Initiation
Ocular Therapeutix initiated  »

Ocular Therapeutix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Dec

VYGR

Voyager Therapeutics

$11.25

-0.54 (-4.58%)

19:49
11/14/18
11/14
19:49
11/14/18
19:49
Upgrade
Voyager Therapeutics rating change  »

Voyager Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

GLPG

Galapagos NV

$103.79

1.03 (1.00%)

19:48
11/14/18
11/14
19:48
11/14/18
19:48
Initiation
Galapagos NV initiated  »

Galapagos NV initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COPY

CopyTele

$0.00

(0.00%)

19:47
11/14/18
11/14
19:47
11/14/18
19:47
Upgrade
CopyTele rating change  »

CopyTele upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VICI

VICI Properties

$21.43

-0.04 (-0.19%)

19:40
11/14/18
11/14
19:40
11/14/18
19:40
Syndicate
VICI Properties 30M share Secondary priced at $21.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

WHD

Cactus

$32.37

-0.7 (-2.12%)

19:37
11/14/18
11/14
19:37
11/14/18
19:37
Hot Stocks
Cactus names Stephen Tadlock new CFO »

Cactus announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RVLT

Revolution Lighting

$1.42

(0.00%)

19:32
11/14/18
11/14
19:32
11/14/18
19:32
Hot Stocks
Revolution Lighting receives revised $1.50 per share proposal from RVL LLC »

Revolution Lighting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$8.34

-0.265 (-3.08%)

19:20
11/14/18
11/14
19:20
11/14/18
19:20
Periodicals
General Electric withdraws from Nigeria rail concession, Reuters says »

GE has withdrawn from a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCSF

Bain Capital Specialty Finance

$0.00

(0.00%)

19:11
11/14/18
11/14
19:11
11/14/18
19:11
Syndicate
Bain Capital Specialty Finance 7.5M share IPO price $20.25 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

TSLA

Tesla

$344.07

5.36 (1.58%)

19:07
11/14/18
11/14
19:07
11/14/18
19:07
Periodicals
Tesla Model 3 owners experience issues in cold weather, Electrek says »

Tesla Model 3 will face…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 19

    Nov

  • 19

    Nov

  • 13

    Dec

NGHC

National General

$24.75

-3.05 (-10.97%)

19:05
11/14/18
11/14
19:05
11/14/18
19:05
Syndicate
National General 5M share Secondary priced at $24.00 »

JPMorgan, Goldman Sachs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 28

    Nov

  • 03

    Dec

  • 04

    Dec

  • 15

    Nov

WMT

Walmart

$101.58

-1.37 (-1.33%)

19:01
11/14/18
11/14
19:01
11/14/18
19:01
Periodicals
Walmart's Cornershop to expand into Canada next year, Reuters says »

Cornershop, a Latin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

WUBA

58.com

$60.54

1.65 (2.80%)

, CSCO

Cisco

$44.35

-0.78 (-1.73%)

18:54
11/14/18
11/14
18:54
11/14/18
18:54
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: 58.com…

WUBA

58.com

$60.54

1.65 (2.80%)

CSCO

Cisco

$44.35

-0.78 (-1.73%)

VIPS

Vipshop

$5.35

0.105 (2.00%)

SFS

Smart & Final Stores

$4.96

-0.2 (-3.88%)

NTES

NetEase

$219.69

5.51 (2.57%)

SVMK

SurveyMonkey

$12.78

1.455 (12.85%)

ORCL

Oracle

$48.84

-0.68 (-1.37%)

WP

Worldpay

$82.71

-2.74 (-3.21%)

CDTI

CDTi

$1.49

-0.03 (-1.97%)

APVO

Aptevo Therapeutics

$3.13

-0.09 (-2.80%)

NTAP

NetApp

$78.05

-0.85 (-1.08%)

HSDT

Helius Medical

$9.20

-0.57 (-5.83%)

MGI

MoneyGram

$2.14

-0.09 (-4.04%)

CASI

Casi Pharmaceuticals

$3.33

0.025 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 26

    Nov

  • 27

    Nov

  • 05

    Dec

  • 06

    Dec

  • 10

    Dec

  • 10

    Jan

  • 15

    Nov

ECOL

US Ecology

$69.90

0.06 (0.09%)

18:48
11/14/18
11/14
18:48
11/14/18
18:48
Earnings
US Ecology backs FY18 adj. EPS view $2.28-$2.44, consensus $2.35 

:

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECOL

US Ecology

$69.90

0.06 (0.09%)

18:47
11/14/18
11/14
18:47
11/14/18
18:47
Hot Stocks
US Ecology purchases Ecoserv Industrial Disposal »

US Ecology has acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$144.25

2.06 (1.45%)

18:36
11/14/18
11/14
18:36
11/14/18
18:36
Periodicals
Facebook execs aimed to hide election meddling, propaganda on platform, NYT says »

Facebook CEO Mark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$270.19

-1.81 (-0.67%)

18:22
11/14/18
11/14
18:22
11/14/18
18:22
Periodicals
China delivers written response to U.S. trade reform demands, Reuters says »

China has sent a written…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$270.19

-1.81 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OI

Owens-Illinois

$17.50

0.74 (4.42%)

18:18
11/14/18
11/14
18:18
11/14/18
18:18
Earnings
Owens-Illinois sees FY19 EPS growth of over 10% »

Sees FY19: Segment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.